Low-Concentration Atropine Market 2024-2028, Poised for Growth Amid Rising Awareness of Vision Care

The Global Low-Concentration Atropine Market is projected to grow by USD 1,039.97 million at a CAGR of 18.81% from 2023 to 2028. Increasing awareness regarding vision care, technological advancements, and growing healthcare expenditure are driving market expansion.

For more details about the industry, get the PDF sample report for free

Market Segmentation

By Type:

Atropine sulfate 0.01 percentage
Atropine sulfate 0.025 percentage
Atropine sulfate 0.05 percentage

By Application:

Child
Adult

By Geography:

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Rest of Europe
Asia
- China
- India
Rest of the World (ROW)
- Australia
- Argentina
- Brazil

Market Drivers

Growing demand for vision correction among the aging population.
- The aging population is a major driver, as visual impairment risks increase with age.
- Increased screen time and digital exposure further contribute to myopia prevalence.
Advancements in technology and lifestyle changes.
- Rising awareness about vision disorders due to increased access to healthcare.

Market Trends

Growing focus on funding for myopia research studies.
- In August 2021, Sydnexis secured USD 45 million in Series B financing to support its SYD-101 candidate for treating progressive myopia in children.
- In December 2022, SUNY College of Optometry received a USD 2.34 million grant from the National Eye Institute (NEI) to study eye growth and myopia development.

Market Challenges

Side effects and uncertainty in the efficacy of low-concentration atropine.
- Potential side effects include mydriasis, photophobia, blurred near vision, and allergic responses.
- Long-term use may lead to dilated pupils, dry eyes, headaches, and urinary retention.
- Low efficacy of 0.01% atropine concentration limits its widespread adoption.

Get more details by ordering the complete report